Source: Securities-Hongan Studio
On November 12, the Wohua Medicine plate rose 2.13 2.13%, As of 10:17, reported at 5.27 yuan/share, with a turnover of 18.127 million yuan, a renewal rate of 0.61%, and a total market value of 3.042 billion yuan.
In terms of the flow of funds, the main funds have a net outflow of 741,100 yuan, and the large orders buy 215,900 yuan, accounting for 1.19%, sold for 957,700 yuan, accounting for 5.28%.
Wohua Pharmaceuticals stock price has fallen by 8.43%this year, 6.04%in the nearly 5 trading days, 14.57%in the past 20th, and 32.08%on the past 60.
Since this year, Wohua Pharmaceutical has been on the Dragon Tiger List once, and the most recently appeared on the Dragon Tiger List to February 7.
Data show, Located at No. 3517, Liyuan Street, Weifang High-tech Industrial Development Zone, Shandong Province.On January 24, 2007, the companys main business involved the research and development, production and sales of pure natural plant cardiovascular and cerebrovascular medicines.The latest annual reports main business income composition is: 36.37%of the Wahua Xin Keshu tablets, 24.30%of Bone Shukang Capsule/Granules, 14.62%of He Dan tablets/capsules, 13.61%of cerebral blood sparse oral solution, and 11.10%.
Shenwan Industry, which belongs to Wahua Pharmaceuticals: Medicine and Bio-Chinese Medicine II-Chinese Medicine III.The concept sector includes: Chinese medicine, prevention, small plate, venture capital, etc.
As of September 30, the number of shareholders of Wohua Pharmaceutical was 37,400, a decrease of 1.19%from the previous period; the per capita circulation shares were 1,5223, an increase of 1.21%over the previous period.From January to September 2024, Wohua Pharmaceutical achieved operating income of 577 million yuan, a year-on-year decrease of 19.50%; the net profit of home mother was 22.909 million yuan, a decrease of 60.09%year-on-year.
In terms of dividends, Wohua Pharmaceutical A shares have cumulative 623 million yuan after listing.In the past three years, a total of 294 million yuan was distributed.
In terms of the position of the institution, as of September 30, 2024, among the top ten circulation shareholders of Wohua Medicine, Huitian Fuzhong SSC ETF (560080) ranked seventh largest mobile shareholder, Holding 1.4079 million shares, an increase of 183,900 shares compared to the previous period.
